Intercept Pharma

Intercept Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline includes OCALIVA, which is used for the treatment of biliary cholangitis, nonalcoholic steatohepatitis, sclerosing cholangitis and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in Morristown, NJ.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q3 2024

Intercept Pharma reports robust earnings, eyes growth amid competitive challenges

Intercept Pharma's Q4 2022 earnings call highlighted strong financial performance, strategic advancements, and a focus on innovation and market expansion.
The company's achievements in sales growth, patent protection, and financial stability position it well for future growth and leadership in the PBC and NASH markets.
Challenges in competitive dynamics and regulatory landscape require proactive strategies, while opportunities in new programs and market developments offer avenues for continued success.
Overall, Intercept Pharma's performance underscores a resilient and forward-thinking approach to navigating the complexities of the pharmaceutical industry and driving sustainable growth.

Intercept Pharma reports growth in sales and navigates NASH landscape

Intercept Pharma's Q1 2023 performance saw growth in net sales and strong sales performance of OCALIVA.
The company's focus on F3-like NASH patients and competitive positioning of OCA are key strengths.
Challenges include pricing strategy discussions and questions on combination approaches.
Opportunities lie in addressing AdCom discussions, expanding prescriber base, and preventing cirrhosis progression.

Intercept Pharma reports strong Q2 earnings, eyes FDA relations

Intercept Pharma's strong performance in Q2 2023 shows progress towards profitability by 2024. The company is addressing challenges in FDA relations and study enrollments while leveraging market opportunities for growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Intercept Pharmaceuticals is a biopharmaceutical company, that engages in discovering and developing small molecule drugs and therapeutics for the treatment of chronic fibrotic and metabolic diseases. It offers INT-747, an FXR modulating agent that treats patients with chronic autoimmune liver diseases. The company's drug development programs also focus on modulating bile acid receptors, and amelioration of metabolic and hepatic functions in chronic liver diseases.

Intercept Pharmaceuticals' liver disease drug can cause injury to the organ in patients without severe scarring, the U.S. Food and Drug Administration said on Thursday, based on its review of postmarket clinical trial data.

US FDA says Intercept's drug can cause liver injury in patients without scarring

The U.S. Food and Drug Administration on Tuesday declined full approval for Intercept Pharmaceuticals' liver disease drug, raising questions about its future in the market.

US FDA declines full approval for Intercept's liver disease drug

MORRISTOWN, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a wholly owned biopharmaceutical subsidiary of Alfasigma S.p.A., today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) that addresses the supplemental New Drug Application (sNDA) for OCALIVA® (obeticholic acid, OCA) seeking full approval for the treatment of indicated patients with primary biliary cholangitis (PBC) – a rare, progressive disease that disproportionally affects women.

Intercept Receives Complete Response Letter from FDA Addressing OCALIVA supplemental New Drug Application (sNDA)

Independent advisers to the U.S. Food and Drug Administration voted on Friday against confirmatory trial data for Intercept Pharmaceuticals' liver disease drug, putting into question the treatment's future in the U.S. market.

FDA advisers vote against confirmatory data for Intercept's liver disease drug

The U.S. Food and Drug Administration's staff on Wednesday raised concerns over the efficacy of Intercept Pharmaceuticals' liver disease drug, which is awaiting the regulator's traditional approval.

FDA staff raises efficacy concerns over Intercept's liver disease drug

MORRISTOWN, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for Ocaliva for the treatment of individuals with primary biliary cholangitis (PBC). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of October 15, 2024. In this communication, the agency informed Intercept that they are planning to hold an Advisory Committee meeting to discuss the application.

Intercept Announces FDA Acceptance of Supplemental New Drug Application for Ocaliva® (obeticholic acid) for the Treatment of PBC

BOLOGNA, Italy and MORRISTOWN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alfasigma S.p.A. (“Alfasigma”) and Intercept Pharmaceuticals, Inc. (“Intercept”) announced today the completion of the acquisition of Intercept by Alfasigma through its wholly owned subsidiary Interstellar Acquisition Inc.

Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc.

BOLOGNA, Italy--(BUSINESS WIRE)--Alfasigma S.p.A. (“Alfasigma”) announced today that it has, through its wholly owned subsidiary Interstellar Acquisition Inc. (“Interstellar”), successfully completed its tender offer to purchase all outstanding shares of common stock of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) (“Intercept”), at a price of USD 19.00 per share, net to the seller thereof in cash, without interest, less any applicable withholding of taxes. The tender offer expired as schedule.

Alfasigma S.p.A. successfully completes tender offer for all outstanding shares of common stock of Intercept Pharmaceuticals, Inc.

Intercept (ICPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Intercept Pharmaceuticals (ICPT) Report Negative Q3 Earnings? What You Should Know

BOLOGNA, Italy--(BUSINESS WIRE)--Alfasigma S.p.A. (“Alfasigma”) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the “HSR Act”) with respect to Alfasigma's proposed acquisition of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) (“Intercept”) expired at 11:59 p.m. on October 25, 2023. The expiration of the HSR Act waiting period satisfies one of the conditions to consummate the tender offer. Other customary offer conditions remain to.

Alfasigma S.p.A. Announces Expiration of Hart-Scott-Rodino Waiting Period in Connection with Pending Acquisition of Intercept Pharmaceuticals, Inc.

Chico's FAS

Hersha Hospitality Trust Class A

NextGen Healthcare Inc

Park-Ohio Holdings

Hostess Brands

Splunk

In rough markets it's important to keep and eye out for overbought stocks. Finding the right timing to buy and sell stocks will always be a sought-after skill by any investor searching for that holy grail.

Stocks to Sell: 7 Overbought Companies You Ought to Dump Right Now

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Intercept Pharmaceuticals, Inc. (NasdaqGS: ICPT) to Alfasigma S.p.A. Under the terms of the proposed transaction, shareholders of Intercept will receive $19.00 in cash for each share of Intercept that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate,.

INTERCEPT PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intercept Pharmaceuticals, Inc. - ICPT

BOLOGNA, Italy--(BUSINESS WIRE)--Alfasigma S.p.A. (“Alfasigma”) today announced that its wholly-owned subsidiary, Interstellar Acquisition Inc., a Delaware corporation (“Purchaser”), has commenced a cash tender offer to purchase all of the outstanding shares of common stock, par value USD $0.001 per share, of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) (“Intercept”) for a price of USD $19.00 per share, net to the holder thereof in cash, without interest, less any applicable withholding of ta.

Alfasigma S.p.A. Tender Offer for Intercept Pharmaceuticals, Inc. Commences

LOS ANGELES, CA / ACCESSWIRE / September 27, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Intercept Pharmaceuticals, Inc. ("Intercept" or "the Company") (NASDAQ:ICPT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm

Intercept Pharmaceuticals (ICPT) gains an acquisition deal from Alfasigma for $19.00 per share in cash.

Intercept Pharmaceuticals (ICPT) Surges on Acquisition Deal

Intercept (ICPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Intercept (ICPT) Stock Jumps 79.2%: Will It Continue to Soar?

The stock is exploding following an announcement that it's on track to be acquired. Alfasigma is poised to buy Intercept at a price of $19 per share.

Why Intercept Pharmaceuticals Stock Is Skyrocketing Today

Amid a rough day on Wall Street, Intercept Pharmaceuticals (NASDAQ: ICPT ) represented a bright spot, with shares swinging up 75% before slightly adding to those gains. Catapulting the biopharmaceutical specialist was the announcement that Italy-based Alfasigma will acquire Intercept, seeking to leverage its lead therapeutic Ocaliva.

Why Is Intercept Pharmaceuticals (ICPT) Stock Up 75% Today?

MILWAUKEE , Sept. 26, 2023 /PRNewswire/ -- Ademi LLP is investigating Intercept (Nasdaq: ICPT) for possible breaches of fiduciary duty and other violations of law in its transaction with Alfasigma.

Shareholder Alert: Ademi LLP investigates whether Intercept Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Alfasigma

Intercept Pharmaceuticals (NASDAQ:ICPT) Inc shares surged 79% to $18.64 in late-morning trading on Tuesday after the biopharmaceutical company specializing in rare and serious liver diseases announced that it has agreed to be acquired by Alfasigma SpA, one of Italy's largest pharma companies, for $19 per share in cash, or an 82% premium to Intercept's closing price on September 25, 2023.  Intercept's lead medicine is Ocaliva, the only US Food and Drug Administration (FDA) approved second-line treatment for primary biliary cholangitis (PBC), a progressive autoimmune disease affecting the liver, which generated revenue of $152 million during the first half of 2023.

Intercept Pharmaceuticals stock soars on Alfasigma acquisition deal

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) to Alfasigma S.p.A. for $19.00 per share in cash is fair to Intercept shareholders. Halper Sadeh encourages Intercept shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns wheth.

ICPT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Intercept Pharmaceuticals, Inc. Is Fair to Shareholders

Shares of Intercept Pharmaceuticals Inc. ICPT, -0.38% were set to soar Tuesday, after the biopharmaceutical company announced an agreement to be acquired by Italy's Alfasigma S.p.A in a deal that values Intercept shares at an 82% premium. Intercept's stock has been halted for news until 8:30 a.m.

Intercept Pharmaceuticals' stock set to soar after Alfasigma buyout deal for an 82% premium

BOLOGNA, Italy and MORRISTOWN, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Alfasigma S.p.A (“Alfasigma”), one of Italy's leading pharmaceutical companies, and Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT, “Intercept”), a leading biopharmaceutical company in rare and serious liver diseases, today announced that they have entered into a definitive merger agreement under which Alfasigma has agreed to acquire Intercept for $19.00 per share in cash. The anticipated transaction will materially expand Alfasigma's gastrointestinal and hepatology portfolio and its presence in the U.S. market.

Alfasigma to Acquire Intercept Pharmaceuticals for $19.00 per Share in Cash, Expanding the Global Footprint of Alfasigma Via a Leader in Rare and Serious Liver Diseases

Intercept (ICPT) reported earnings 30 days ago. What's next for the stock?

Why Is Intercept (ICPT) Up 0.6% Since Last Earnings Report?

Intercept (ICPT) reports a lower net loss and beats on revenues in the second quarter. The company also updates its guidance for its lead drug, Ocaliva.

News for Intercept Pharma Stock (ICPT)